US9669021 — Sublingual apomorphine
Method of Use · Assigned to Sunovion Pharmaceuticals Inc · Expires 2030-06-11 · 4y remaining
What this patent protects
This patent protects methods of treating Parkinson's disease by administering a sublingual film containing apomorphine particles.
USPTO Abstract
Disclosed are methods of treating Parkinson's disease by (i) providing a pharmaceutical composition in unit dosage form that is a film having a first portion including apomorphine particles containing an acid addition salt of apomorphine and a second portion containing a pH neutralizing agent, where the film contains the acid addition salt of apomorphine in an amount effective to treat Parkinson's disease, and (ii) administering the film by placing the film sublingually in the mouth of the subject and contacting sublingual mucosal tissue with the film.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2825 |
— | apomorphine-hydrochloride |
U-2825 |
— | apomorphine-hydrochloride |
U-2825 |
— | apomorphine-hydrochloride |
U-2825 |
— | apomorphine-hydrochloride |
U-2825 |
— | apomorphine-hydrochloride |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.